Nieuws en video's - TELIX PHARMACEUTICALS LIMITED

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals PR Newswire MELBOURNE, Australia, Nov. 4, 2024 MELBOURNE, Australia , Nov. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals [1] for Medicare Fee for Service patients in the hospital outpatient...

MELBOURNE, Australia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialized diagnostic radiopharmaceuticals 1 for Medicare Fee for Service patients in the hospital outpatient setting, beyond the transitional pass-through payment period (“pass-through”). This is a significant decision for patients and...

MELBOURNE, Australia, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET 1 product, Illuccix® ( 68 Ga-PSMA-11). Subtle Medical’s SubtlePET™ is a U.S. Food and Drug Administration (FDA) cleared AI-driven solution to enhance the efficiency and...

MELBOURNE, Australia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara® 1 ), an agent for the imaging of glioma. The application has been granted priority review and designated a PDUFA 2 goal date of 26 April 2025, paving the way for a U.S. commercial launch in 2025 3 . Pixclara ( 18 F-floretyrosine or...

MELBOURNE, Australia, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the spin-off of Rhine Pharma 1 , which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m ( 99m Tc) and rhenium-188 ( 188 Re). Rhine Pharma was formed following a collaboration between Telix and Heidelberg University Hospital (UKHD), which aimed to...

MELBOURNE, Australia, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that it has publicly filed a Form 20-F registration statement (Registration Statement) with the United States (U.S.) Securities and Exchange Commission (SEC) relating to a proposed listing of American Depository Shares (ADS), representing the Company’s ordinary shares, on the Nasdaq Stock Market (Nasdaq). The proposed Nasdaq listing is expected to be established as a...

Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M PR Newswire MELBOURNE, Australia, Oct. 17, 2024 MELBOURNE, Australia , Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed Unaudited total revenue of approximately US$135 million (AU$201 million [1] ), primarily generated from...

MELBOURNE, Australia, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed Unaudited total revenue of approximately US$135 million (AU$201 million 1 ), primarily generated from sales of Telix’s prostate cancer imaging product Illuccix® in the Precision Medicine (Px) business unit. This...

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that Health Canada has approved the use of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA 1 -targeted radionuclide therapy. The label expansion means that Illuccix is now approved in Canada to select patients with progressive metastatic castration-resistant prostate cancer (mCRPC) for treatment with the...

MELBOURNE, Australia, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a Phase II trial exploring the clinical utility of Telix’s first-in-class investigational PET 1 agent, TLX250-CDx ( 89 Zr-girentuximab) in recurrent clear cell renal cell carcinoma (ccRCC) after surgery. ‘CA-NINE’ 2 – led by Professor Brian Shuch at University of California, Los Angeles (UCLA) – is a Phase II...

MELBOURNE, Australia and INDIANAPOLIS, Ind. and LAKE MARY, Fla., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS (USA) Inc. (RLS, RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET 1 , SPECT 2 and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The acquisition significantly expands Telix’s North...

MELBOURNE, Australia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE: CAH, Cardinal Health) as a commercial radiopharmaceutical distributor to supply finished unit doses of its PET 1 agent, Zircaix® 2 (TLX250-CDx) for the imaging of kidney cancer in the United States (U.S.), subject to regulatory approval. In preparation for a planned commercial rollout, Telix has contracted with...

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that primary results from its Phase III ZIRCON 1 trial have been published in The Lancet Oncology, reporting that Telix’s first-in-class investigational PET 2 agent, TLX250-CDx (Zircaix® 3 , 89 Zr-girentuximab), is highly accurate in detecting and characterizing clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IRMs). In this...

MELBOURNE, Australia, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer. TLX101 (4-L-[ 131 I]...

MELBOURNE, Australia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara™ 1 , 18 F-floretyrosine or 18 F-FET), an investigational PET 2 agent for the characterization of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients. Given the...

MELBOURNE, Australia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology. The updated business model comprises: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech) and Telix Manufacturing Solutions...

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities PR Newswire MELBOURNE, Australia, Aug. 22, 2024 MELBOURNE, Australia , Aug. 22, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024 . All figures are in AU$ unless otherwise stated. [1] H1 2024 financial highlights Total Group revenue of $364.0 million , an increase of 65% compared to H1...

MELBOURNE, Australia, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated. 1 H1 2024 financial highlights Total Group revenue of $364.0 million, an increase of 65% compared to H1 2023, reflecting continued growth in sales of its prostate cancer imaging agent, Illuccix ® in the United States (U.S.), now in its second full year of...

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara™ 1 , 18 F-floretyrosine or 18 F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed. Amino acid PET is included in U.S. and European...

Telix Successfully Prices A$650 Million Convertible Bonds PR Newswire MELBOURNE, Australia, July 24, 2024 MELBOURNE, Australia , July 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as "convertible bonds" (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary...